Searching…
Frontera is a clinical-stage biotech company with a world-class drug discovery and development team, supported by top-notch academic and industrial experts and renowned venture capitals.
Using their APEX technology and manufacturing platform, Frontera is creating adeno-associated virus (AAV) gene expression systems to develop novel gene therapy products with quicker speed-to-market and lower cost.
Jul 19, 2022 · 7 月 19 日，方拓生物科技公司（Frontera Therapeutics）（简称 “方拓生物”）宣布完成 1.6 亿美元 B 轮融资。 B 轮融资由博裕资本和红杉中国领投，正心谷、史带投资等投资机构参与跟投，原股东奥博资本、泓元资本继续加持。
FRONTERA THERAPEUTICS 芳拓生物 基因治疗的创新者 芳拓生物，致力为全球患者提供 创新的、高质量的、可支付的rAAV基因治疗药物 芳拓生物是一家临床阶段的国际化生物技术公司。
FronteraTherapeutics, with operations in Boston, Shanghai and Suzhou, has raised $160 million in a Series B round to support its lead program, FT-001, in clinical trials. The company develops recombinant adeno-associa...
Jul 21, 2022 · Headquartered in Bedford, Massachusetts and Suzhou, China, Frontera focuses on gene therapies. Its novel APEX Technology & Manufacturing platform is an adeno-associated virus (AAV) gene expression syste...
Sep 29, 2025 · 作为全产业链布局的创新型生物制药公司，迈威生物拥有国际领先的ADC药物开发平台，并已获得临床验证，具备强大的研发实力和商业化潜力。
